Linked Life Data

10545390

Source:http://linkedlifedata.com/resource/pubmed/id/10545390

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1999-12-10
pubmed:abstractText
In experimental animal models of multiple sclerosis demyelinating antibody responses are directed against the myelin oligodendrocyte glycoprotein (MOG). We have investigated whether a similar antibody response is also present in multiple sclerosis patients. Using the recombinant human extracellular immunoglobulin domain of MOG (MOG-Ig) we have screened the sera and CSFs of 130 multiple sclerosis patients, 32 patients with other inflammatory neurological diseases (OIND), 30 patients with other non-inflammatory neurological diseases (ONND) and 10 patients with rheumatoid arthritis. We report that 38% of multiple sclerosis patients are seropositive for IgG antibodies to MOG-Ig compared with 28% seropositive for anti-myelin basic protein (MBP). In contrast, OIND are characterized by similar frequencies of serum IgG antibody responses to MOG-Ig (53%) and MBP (47%), whereas serum IgG responses to MOG-Ig are rare in ONND (3%) and rheumatoid arthritis (10%). Anti-MBP IgG antibodies, however, are a frequent finding in ONND (23%) and rheumatoid arthritis (60%). Our results provide clear evidence that anti-MOG-Ig antibodies are common in CNS inflammation. However, in OIND these antibody responses are transient, whereas they persist in multiple sclerosis. We demonstrate that the serum anti-MOG-Ig response is already established in early multiple sclerosis (multiple sclerosis-R0; 36%). In later multiple sclerosis stages frequencies and titres are comparable with early multiple sclerosis. In contrast, the frequency of anti-MBP antibodies is low in multiple sclerosis-R0 (12%) and increases during disease progression in relapsing-remitting (32%) and chronic progressive multiple sclerosis (40%), thus suggesting that anti-MBP responses accumulate over time. Finally we provide evidence for intrathecal synthesis of IgG antibodies to MOG-Ig in multiple sclerosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0006-8950
pubmed:author
pubmed:issnType
Print
pubmed:volume
122 ( Pt 11)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2047-56
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:10545390-Adult, pubmed-meshheading:10545390-Arthritis, Rheumatoid, pubmed-meshheading:10545390-Autoantibodies, pubmed-meshheading:10545390-Blotting, Western, pubmed-meshheading:10545390-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10545390-Female, pubmed-meshheading:10545390-Humans, pubmed-meshheading:10545390-Immunoglobulins, pubmed-meshheading:10545390-Male, pubmed-meshheading:10545390-Middle Aged, pubmed-meshheading:10545390-Multiple Sclerosis, pubmed-meshheading:10545390-Myelin Basic Proteins, pubmed-meshheading:10545390-Myelin Proteins, pubmed-meshheading:10545390-Myelin-Associated Glycoprotein, pubmed-meshheading:10545390-Nervous System Diseases, pubmed-meshheading:10545390-Neuritis, pubmed-meshheading:10545390-Recombinant Proteins, pubmed-meshheading:10545390-Retrospective Studies
pubmed:year
1999
pubmed:articleTitle
Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
pubmed:affiliation
Department of Neurology, University of Innsbruck, Innsbruck, Austria and Department of Neuroimmunology, Max Planck Institute for Neurobiology, Martinsried, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't